73 articles - From Friday Jun 03 2022 to Friday Jun 10 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
| Ann Intern Med |
Cannabis-Based Products for Chronic Pain : A Systematic Review. Oral, synthetic cannabis products with high THC-to-CBD ratios and sublingual, extracted cannabis products with comparable THC-to-CBD ratios may be associated with short-term improvements in chronic pain and increased risk for dizziness and sedation. Studies are needed on long-term outcomes and further evaluation of product formulation effects. Primary funding source Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services. (PROSPERO CRD42021229579). |
RCT, clinical trials, retrospective studies, etc…
| Ann Intern Med |
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial. The findings suggest there are additional important clinical benefits of molnupiravir beyond reduction in hospitalization or death. Primary funding source Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. |
| Lancet |
Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study. Therefore, IUD insertion timing should be based on individual desire for IUD contraception and patient convenience to assure an IUD insertion can occur. Careful follow-up of individuals at higher risk of uterine perforation is warranted. Funding Bayer AG. |
| N Engl J Med |
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. Methods In a registrational phase 2 cohort, we evaluated adagrasib (600 mg orally twice daily) in patients with -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials. gov number, NCT03785249.). |
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. A ctDNA-guided approach to the treatment of stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival. (Supported by the Australian National Health and Medical Research Council and others; DYNAMIC Australian New Zealand Clinical Trials Registry number, ACTRN12615000381583.). |
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. Ibrutinib treatment in combination with standard chemoimmunotherapy significantly prolonged progression-free survival. The safety profile of the combined therapy was consistent with the known profiles of the individual drugs. (Funded by Janssen Research and Development and Pharmacyclics; SHINE ClinicalTrials.gov number, NCT01776840.). |
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. Treatment with dulaglutide at a once-weekly dose of 0.75 mg or 1.5 mg was superior to placebo in improving glycemic control through 26 weeks among youths with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI. (Funded by Eli Lilly; AWARD-PEDS ClinicalTrials.gov number, NCT02963766.). |
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. Mismatch repair-deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.). |
Teclistamab in Relapsed or Refractory Multiple Myeloma. Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.). |
Tirzepatide Once Weekly for the Treatment of Obesity. In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.). |
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast04 ClinicalTrials.gov number, NCT03734029.). |
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. Among adults with multiple myeloma, RVD plus ASCT was associated with longer progression-free survival than RVD alone. No overall survival benefit was observed. (Funded by the National Heart, Lung, and Blood Institute and others; DETERMINATION ClinicalTrials.gov number, NCT01208662.). |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Lancet |
| N Engl J Med |
Chronic Traumatic Encephalopathy in the Brains of Military Personnel. Evidence of CTE was infrequently found in a series of brains from military personnel and was usually reflected by minimal neuropathologic changes. Risk ratios for CTE were numerically higher among decedents who had contact-sports exposure and other exposures to TBI in civilian life than among those who had blast exposure or other military TBI, but the small number of CTE cases and wide confidence intervals preclude causal conclusions. (Funded by the Department of Defense-Uniformed Services University Brain Tissue Repository and Neuropathology Program and the Henry M. Jackson Foundation for the Advancement of Military Medicine.). |
Letters to the editors and authors’ replies
| Lancet |
| N Engl J Med |
all remaining publications eg case reports, images of the month, etc…
| Ann Intern Med |
| Lancet |
| N Engl J Med |